Medication Regimen to Lower Heart Rate and Blood Pressure
For most patients requiring both heart rate and blood pressure reduction, beta-blockers combined with ACE inhibitors or ARBs, plus a diuretic, represent the optimal evidence-based approach. 1
First-Line Combination Therapy
The most recent 2024 ESC guidelines establish that combination therapy with a RAS blocker (ACE inhibitor or ARB) plus a dihydropyridine calcium channel blocker (CCB) or thiazide/thiazide-like diuretic is recommended as initial treatment for confirmed hypertension (BP ≥140/90 mmHg) 1. However, when heart rate control is specifically needed, the approach must be modified.
When Heart Rate Control is Required
Beta-blockers should be combined with other major BP-lowering drug classes when there are compelling indications such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or specifically for heart rate control 1. The 2025 AHA/ACC guidelines and 2024 ESC guidelines both emphasize that beta-blockers are not first-line monotherapy for hypertension alone, but become essential when heart rate reduction is a therapeutic goal 2, 3.
Specific Beta-Blocker Recommendations
Among beta-blockers, carvedilol, metoprolol succinate, and bisoprolol have demonstrated improved outcomes in heart failure and are effective in lowering both BP and heart rate 4. These agents reduce heart rate by approximately 10-12 beats/min at standard doses 5, 6.
- Atenolol: 25-100 mg twice daily (reduces HR by ~12 beats/min) 6
- Metoprolol succinate: 50-200 mg once daily 7
- Bisoprolol: 2.5-10 mg once daily 7
- Carvedilol: 12.5-50 mg twice daily 7
Alternative: Non-Dihydropyridine Calcium Channel Blockers
For patients who cannot tolerate beta-blockers, non-dihydropyridine CCBs (diltiazem or verapamil) provide both BP and heart rate reduction 8, 9, 10. Diltiazem sustained-release 200-300 mg once daily reduces elevated heart rate with an increasing effect at higher baseline rates, while avoiding excessive bradycardia in patients with normal baseline heart rates 9.
Dosing for Non-Dihydropyridine CCBs:
- Diltiazem sustained-release: 200-300 mg once daily 9, 10
- Verapamil sustained-release: 240 mg once or twice daily 10
Critical caveat: Non-dihydropyridine CCBs (verapamil and diltiazem) should be avoided in patients with heart failure 4.
Practical Treatment Algorithm
Step 1: Initial Dual Therapy
Start with ACE inhibitor or ARB + beta-blocker (if heart rate control needed) or ACE inhibitor/ARB + dihydropyridine CCB (if heart rate control not primary concern) 1.
Step 2: Add Diuretic if Needed
If BP remains uncontrolled, escalate to three-drug combination: RAS blocker + beta-blocker + thiazide-like diuretic (chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg) 2, 3.
Step 3: Resistant Hypertension
If BP remains ≥130/80 mmHg on three drugs, add spironolactone 25-50 mg daily (if eGFR ≥45 mL/min/1.73 m²) 2, 3.
Important Clinical Considerations
Avoid combining two drugs from the same class or that target the same system 7. Specifically, do not combine ACE inhibitors with ARBs, as this increases cardiovascular and renal risk 7, 1.
Target BP is 120-129/70-79 mmHg according to the most recent 2024 ESC guidelines 1. The 2025 AHA/ACC guidelines recommend <130/80 mmHg 2, 3.
Heart rate reduction is particularly beneficial in patients with baseline heart rate >80-85 beats/min, as elevated heart rate is an independent cardiovascular risk factor 11. Beta-blockers show greatest benefit in reducing heart rate when baseline is ≥85 beats/min 6.
Special Populations
For elderly patients (≥85 years), those with moderate-to-severe frailty, or symptomatic orthostatic hypotension, consider starting with monotherapy and slower up-titration rather than initial combination therapy 1.
For patients with coronary artery disease, the combination of beta-blocker with ACE inhibitor provides both symptomatic relief and prognostic benefit 12.
Single-pill combination therapy is strongly recommended when using combination treatment to improve adherence 1, 13.